Organizing Committee Office

Division of Gastroenterology,
Department of Medicine,
Kurume University
School of Medicine

67 Asahi-machi, Kurume
830-0011, JAPAN

Conference Secretariat

c/o Convention Linkage, Inc.

Daisan Hakata Kaisei Bldg.,
1-3-6, Hakata-eki-minami,
Hakata-ku, Fukuoka-shi,
Fukuoka, 812-0016, Japan
TEL: +81-92-437-4188
FAX: +81-92-437-4182
E-mail:jshilc2021@c-linkage.co.jp

Program

Scientific Program

Day 1: Saturday, October 2, 2021

[Room 1]

Session I   8:30-10:00

Systemic therapy for HCC (TKI, ICI and others)

Chair:
Masafumi Ikeda
National Cancer Center Hospital East, Japan
Sadahisa Ogasawara
Chiba University, Japan
Ann-Lii Cheng
National Taiwan University Cancer Center, Taiwan.

Session Ⅰ-1

Sequential changes in growth factors during lenvatinib
treatment in patients with unresectable hepatocellular carcinoma

Zijian Yang
 
Zijian Yang
Hokkaido University, Sapporo, Japan

Session Ⅰ-2

Progress of systematic therapy for HCC in Asia

Stephen L. CHAN
 
Stephen L. CHAN
The Chinese University of Hong Kong, Hong Kong SAR, China

Session Ⅰ-3

Recent progress of systemic therapy for HCC in Japan
- evidence and clinical practice

Hiroshi Aikata
 
Hiroshi Aikata
Hiroshima University, Japan

Session Ⅰ-4

Advances in Systemic Therapy in HCC

Richard S. Finn
 
Richard S. Finn
David Geffen School of Medicine at University of
California Los Angeles, USA

Workshop I 10:05-11:35

Real-world experience of immunotherapy for HCC

Chair:
Shuichi Kaneko
Kanazawa University, Japan
Hironori Koga
Kurume University School of Medicine, Japan
Pei-Jer Chen
National Taiwan University Hospital, Taiwan

Workshop I-1

Immunotherapy in HCC

Bruno Sangr
 
Bruno Sangro
Clinica Universidad de Navarra, Spain

Workshop I-2

Real-world experience of immunotherapy for HCC in Singapore

David Tai
 
David Tai
National Cancer Centre, Singapore, Singapore

Workshop I-3

Efficacy and risk of HBV reactivation of immune checkpoint inhibitors
treatment for unresectable HCC: real-world experience from Taiwan

Yi-Hsiang Huang
 
Yi-Hsiang Huang
National Yang Ming Chiao Tung University, Taiwan

Workshop I-4

Initial experiences of atezolizumab combined with bevacizumab in
patients with advanced hepatocellular carcinoma: Retrospective analysis
at five institutions in Japan

Miyuki Nakagawa
 
Miyuki Nakagawa
Chiba University, Japan

Symposium I 14:10-17:10

Treatment for BCLC-B

Chair:
Tetsuo Takehara
Osaka University, Japan
Tatsuya Yamashita
Kanazawa University, Japan
Riccardo Lencioni
University of Pisa, Italy
Richard S. Finn
University of California Los Angeles, USA

Symposium I-1

Treatment choice for intermediate stage (up-to-7 in) HCC

Kazuhiro Nouso
 
Kazuhiro Nouso
Okayama City Hospital, Japan

Symposium I-2

Treatment choice for patients with intermediate stage hepatocellular
carcinoma; a single center retrospective study.

Noriyo Yamashiki
 
Noriyo Yamashiki
Kansai Medical University, Japan

Symposium I-3

A new therapeutic strategy for BCLC stage B
~Combination approach with local and systemic therapy to
achieve a loco-regional cure ~

Kaoru Tsuchiya
 
Kaoru Tsuchiya
Musashino Red Cross Hospital, Japan

Symposium I-4

Treatment of BCLC-B stage hepatocellular carcinoma: Korean
perspectives

Seung Up Kim
 
Seung Up Kim
Yonsei University, Korea

Symposium I-5

Systemic treatments in patients with BCLC-B stage hepatocellular
carcinoma

Atsushi Hiraoka
 
Atsushi Hiraoka
Ehime Prefectural Central Hospital, Japan

Symposium I-6

Management of BCLC stage B HCC-evolving new strategies

Andrew X. Zhu
 
Andrew X. Zhu
Massachusetts General Hospital, USA

[Room 2]

Session Ⅱ   8:30-10:00

Technical tips for HCC (Surgery/IVR/PRFA/Radiation)

Chair:
Namiki Izumi
Musashino Red Cross Hospital, Japan
Mitsuo Shimada
Tokushima University, Japan
Bruno Sangro
Clinica Universidad de Navarra, Spain
Jinsil Seong
Yonsei University, Korea

Session Ⅱ-1

The Changing Face of HCC in the United States: Evolution of
Demographics and Treatment

Myron Schwartz
 
Myron Schwartz
Icahn School of Medicine at Mount Sinai, USA

Session Ⅱ-2

Ablation in Japan: SURF trial, new-generation MWA,
ablation with systemic therapy, and ablation webinar

Shuichiro Shiina
 
Shuichiro Shiina
Juntendo University, Japan

Session Ⅱ-3

Advances in transarterial chemoembolization for hepatocellular carcinoma

Shiro Miyayama
 
Shiro Miyayama
Fukui-ken Saiseikai Hospital, Japan

Session Ⅱ-4

Hepatic arterial infusion chemotherapy (HAIC) for long-term prognosis in
patients with advanced hepatocellular carcinoma involving vascular
invasion

Hiroaki Nagamatsu
 
Hiroaki Nagamatsu
Juntendo University, Japan

Session Ⅲ  10:05-11:35

Surgical therapy (including liver transplantation)

Chair:
Susumu Eguchi
Nagasaki University, Japan
Tomoharu Yoshizumi
Kyushu University, Japan
Myron Schwartz
Icahn School of Medicine at Mount Sinai,USA

Session Ⅲ-1

Open hepatectomy for hepatocellular carcinoma in future

Kiyoshi Hasegawa
 
Kiyoshi Hasegawa
The University of Tokyo, Japan

Session Ⅲ-2

Laparoscopic and robotic hepatectomy for hepatocellular carcinoma

Gi Hong Choi
 
Gi Hong Choi
Yonsei University, Korea

Session Ⅲ-3

Current status of liver transplantation for hepatocellular carcinoma
in Japan

Toru Ikegami
 
Toru Ikegami
The Jikei University School of Medicine, Japan

Session Ⅲ-4

Surgical and oncological outcomes of conversion surgery for initially
unresectable locally advanced hepatocellular carcinoma at Kurume
University ~Hepatic arterial infusion chemotherapy with New FP
regimen~

Yuichi Goto
 
Yuichi Goto
Kurume University, Japan

Session Ⅳ  14:10-17:10

Basic Research for HCC and CCC

Chair:
Hirohisa Yano
Kurume University, Japan
Tatsuya Kanto
National Center for Global Health and Medicine, Japan
Lewis R. Roberts
Mayo Clinic College of Medicine and Science, USA

Session Ⅳ-1

Novel molecular targets of cholangiocarcinoma and their translational
implications for drug development

Lewis R. Roberts
 
Lewis R. Roberts
Mayo Clinic College of Medicine and Science, USA

Session Ⅳ-2

Recent progress in basic and clinical research of liver cancer stem
cells

Taro Yamashita
 
Taro Yamashita
Kanazawa University Hospital, Japan

Session Ⅳ-3

The phosphorylated retinoid X receptor-α promotes diethylnitrosamine-
induced hepatocarcinogenesis in mice through the activation of
β-catenin signaling pathway.

Hiroyasu Sakai
 
Hiroyasu Sakai
Gifu University, Japan

Session Ⅳ-4

Stemness and heterogeneity in liver cancer

Shinji Tanaka
 
Shinji Tanaka
Tokyo Medical and Dental University, Japan

Session Ⅳ-5

Drivers of cancer evolution in hepatocellular carcinoma: role in
biomarker discovery

Augusto Villanueva
 
Augusto Villanueva
Icahn School of Medicine at Mount Sinai, USA

Session Ⅳ-6

Multiomics profiling identifies the pro-tumoral immune networks in the
steatotic tumor microenvironment in non-viral hepatocellular
carcinoma

Takahiro Kodama
 
Takahiro Kodama
Osaka University, Japan

Session Ⅳ-7

Intratumoural immune heterogeneity as a hallmark of tumour evolution
in hepatocellular carcinoma

Valerie Chew Suk Peng
 
Valerie Chew Suk Peng
SingHealth-DukeNUS Academic Medical Centre, Singapore

Session Ⅳ-8

Hepatocyte stellate cells in HCC lesions promote the growth of
hepatoma cells via autophagy dependent GDF15 secretion

Hayato Hikita
 
Hayato Hikita
Osaka University, Japan

Day 2: Sunday, October 3, 2021

[Room 1]

Workshop Ⅱ   9:00-10:30

The New Talent Workshop(Breakthrough basic researches in HCC for newly developed molecular and immune targeted therapies)

Chair:
Naoya Sakamoto
Hokkaido University, Japan
Koichiro Haruki
The Jikei University School of Medicine, Japan
Takeo Toshima
Kyushu University Beppu Hospital, Japan

Workshop Ⅱ-1

Molecular characteristics and the effectiveness of the combination
therapy of immune checkpoint inhibitor and angiogenesis inhibitor in
aggressive subtype hepatocellular carcinoma

Tomohiko Taniai
 
Tomohiko Taniai
Tokyo Medical and Dental University, Japan

Workshop Ⅱ-2

Novel anti-angiogenic therapy using tumor endothelial cell-specific
microRNA in hepatocellular carcinoma

Hideki Iwamoto
 
Hideki Iwamoto
Kurume University, Japan

Workshop Ⅱ-3

Leukotrienes Derived from Tumor-Infiltrating Macrophages Enhance
the Progression of Hepatocellular Carcinoma

Takuto Nosaka
 
Takuto Nosaka
University of Fukui, Japan

Workshop Ⅱ-4

Phenotypic characterization by single-cell mass cytometry of human
intrahepatic and peripheral NK cells in patients with hepatocellular
carcinoma

Sachiyo Yoshio
 
Sachiyo Yoshio
National Center for Global Health and Medicine, Japan

Invited Lecture Ⅰ10:35-11:35

New Treatment Paradigm for Intermediate/ Advanced Stage HCC

Chair:
Kiwamu Okita
Shunan Memorial Hospital, Japan

Invited Lecuture Ⅰ-1

 

Masatoshi Kudo
 
Masatoshi Kudo
Kindai University, Japan

Symposium Ⅱ  14:10-17:10

Current treatment of HCC; Asia, Europe and USA

Chair:
Masatoshi Kudo
Kindai University, Japan
Naoya Kato
Chiba University, Japan
Peter R. Galle
University Medical Center Mainz, Germany

Symposium Ⅱ-1

Current systemic therapy and treatment strategy for advanced HCC
in Europe

 Peter R. Galle
 
Peter R. Galle
University Medical Center Mainz, Germany

Symposium Ⅱ-2

Downstaging Locally Advanced HCC to curative resection: the
experience of the National Cancer Center Singapore and the Singapore
General Hospital with selective internal radiation therapy (SIRT)

Pierce Kah Hoe Chow
 
Pierce Kah Hoe Chow
Duke-NUS Medical School, Singapore

Symposium Ⅱ-3

Current treatment selection for primary liver cancer in Japan:
Real-world data from a nationwide registry based on multiple
hospitalizations

Kazuya Okushin
 
Kazuya Okushin
The University of Tokyo, Japan

Symposium Ⅱ-4

Transition of molecular target agent therapy and evolution of its
impact in advanced hepatocellular carcinoma: A multicenter,
survival retrospective study

Kazufumi Kobayashi
 
Kazufumi Kobayashi
Chiba University, Japan

Symposium Ⅱ-5

Difference of clinical guidelines for hepatocellular carcinoma
between Japan and overseas; A focus on hepatic arterial
infusion chemotherapy

Kazuomi Ueshima
 
Kazuomi Ueshima
Kindai University, Japan

Symposium Ⅱ-6

Molecular and immune therapies for HCC

Josep M Llovet
 
Josep M Llovet
Icahn School of Medicine at Mount Sinai, USA

[Room 2]

Session Ⅴ    9:00-10:30

New positioning of RFA/TACE/HAIC/TKI in immunotherapy era

Chair:
Hiroko Iijima
Hyogo College of Medicine, Japan
Ryosuke Tateishi
The University of Tokyo Hospital, Japan
Andrew X. Zhu
Massachusetts General Hospital, USA
Kwang-Hyub Han
National Evidence-based Healthcare Collaborating Agency, Korea

Session Ⅴ-1

The efficacy and safety of sequential therapy with lenvatinib and
transarterial chemoembolization for unresectable hepatocellular
carcinoma.

Tatsuya Kakegawa
 
Tatsuya Kakegawa
Musashino Red Cross Hospital, Japan

Session Ⅴ-2

Role and the prognostic factors of hepatic arterial infusion
chemotherapy `New FP` for advanced HCC beyond up to 7 criteria

Takashi Niizeki
 
Takashi Niizeki
Kurume University, Japan

Session Ⅴ-3

The role of tyrosine kinase inhibitor in the era of immune therapy for
patients with hepatocellular

Do Young Kim
 
Do Young Kim
Yonsei University, Korea

Session Ⅴ-4

Locoregional therapies in the era of molecular and immune treatments
for hepatocellular carcinoma

Riccardo Lencioni
 
Riccardo Lencioni
University of Pisa, Italy

Invited Lecture Ⅱ10:35-11:35

The Global Impact of NAFLD: A 2021 Update

Chair:
Kazuhiko Koike
Kanto Centoral Hospital, Japan

Invited Lecuture Ⅱ-1

 

Zobair M Younossi
 
Zobair M Younossi
Inova Medicine Services, USA

Session Ⅵ   14:10-15:40

Forefront diagnosis and treatment of HCC (including AI and liver regenerative treatment)

Chair:
Michiie Sakamoto
Keio University, Japan
Satoshi Mochida
Saitama Medical University, Japan
Kengo Yoshimitsu
Fukuoka University, Japan

Session Ⅵ-1

Liquid biopsy based on sensitive methylated SEPT9 as a prognostic
marker in hepatocellular carcinoma patients treated with molecular
targeted agents

 
Issei Saeki
Yamaguchi University, Japan

Session Ⅵ-2

Genetic analyses of primary liver cancer cell lines using whole-exome
sequencing and fusion gene analysis

Jun Akiba
 
Jun Akiba
Kurume University Hospital, Japan

Session Ⅵ-3

Role of alteration of oncogenic pathways on the
immunological microenvironment of hepatocellular carcinoma and its
clinical implications

Naoshi Nishida
 
Naoshi Nishida
Kindai University, Japan

Session Ⅵ-4

Advanced CT and MRI for Hepatocellular Carcinoma

Takamichi Murakami
 
Takamichi Murakami
Kobe University, Japan

Session Ⅶ   15:40-17:10

Viral Hepatitis/Fibrosis/NASH

Chair:
Norifumi Kawada
Osaka City University, Japan
Atsushi Nakajima
Yokohama City University, Japan
Hitoshi Yoshiji
Nara Medical University, Japan

Session Ⅶ-1

The incidence rates of complications in Japanese patients with
histopathologically-confirmed NAFLD - Expectations for suppression of
cardiovascular diseases and liver-related events with SGLT2 inhibitor
in NAFLD complicated by diabetes mellitus

Norio Akuta
 
Norio Akuta
Toranomon Hospital, Japan

Session Ⅶ-2

Bezafibrate treatment is associated with reduced risk for development
of hepatocellular carcinoma in a large-scale Japanese cohort of PBC
patients

 
Kosuke Matsumoto
Teikyo University, Japan

Session Ⅶ-3

Recent progress and future perspective on antiviral therapy to prevent
HBV-related HCC

Sang Hoon Ahn
 
Sang Hoon Ahn
Yonsei University, South Korea

Session Ⅶ-4

Hepatocellular carcinoma in SVR achieved CHC patients after DAA
treatment

WakitaTakaji
 
Wakita Takaji
National Institute of Infectious Diseases, Japan